Introduction: The COVID-19 pandemic interrupted many aspects of health care, including cancer treatment. This study aims to assess the potential impact of the COVID-19 pandemic on tumor stage migration in the three most common urological malignancies. Methods: Patient and tumor characteristics of patients undergoing inpatient rehabilitation (IR) in one dedicated IR center in 2019 (pre-pandemic) and 2021 (mid-pandemic) were retrospectively evaluated. The study focused on patients after radical prostatectomy (RP) for prostate cancer (PCa), radical cystectomy (RC) for bladder cancer (BCa), or (partial) nephrectomy for kidney cancer (KC). Results: Overall, 9,039 patients (6,898 (76.3%) after RP, 1,427 (15.8%) after RC, 714 (7.9%) after (partial) nephrectomy) were enrolled. A significant decrease of PCa patients suffering from Gleason sum score ≥8 (17.6% vs. 20.5%, p = 0.005) and lymph node metastases (10.9% vs. 13.0%; p = 0.012) was observed. In BCa and KC patients, tumor stage distribution and abundance of lymph node metastases remained stable, while significantly more BCa patients received neoadjuvant chemotherapy (10.4% vs. 20.2%, p = 0.001). Overall, a significant increase in robot-assisted surgery across all investigated malignancies was detected. Conclusions: No stage migration could be detected across the three most common urological malignancies during the COVID-19 pandemic. Therapeutic standards remained high, while oncological outcomes remained relatively unchanged.

Journal Section:
Research Article
Keywords:
Stage migration, COVID-19 pandemic, Prostate cancer, Bladder cancer, Kidney cancer
1.
Gheorghe
A
,
Maringe
C
,
Spice
J
,
Purushotham
A
,
Chalkidou
K
,
Rachet
B
, et al.
Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: a national population-based modelling study in England, UK
.
Eur J Cancer
.
2021
;
152
:
233
–
42
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Maringe
C
,
Spicer
J
,
Morris
M
,
Purushotham
A
,
Nolte
E
,
Sullivan
R
, et al.
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
.
Lancet Oncol
.
2020
;
21
(
8
):
1023
–
34
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Ribal
MJ
,
Cornford
P
,
Briganti
A
,
Knoll
T
,
Gravas
S
,
Babjuk
M
, et al.
European association of Urology guidelines office rapid reaction group: an organisation-wide collaborative effort to adapt the European association of Urology guidelines recommendations to the coronavirus disease 2019 era
.
Eur Urol
.
2020
;
78
(
1
):
21
–
8
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Fallara
G
,
Sandin
F
,
Styrke
J
,
Carlsson
S
,
Lissbrant
IF
,
Ahlgren
J
, et al.
Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic
.
Scand J Urol
.
2021
;
55
(
3
):
184
–
91
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Nossiter
J
,
Morris
M
,
Parry
MG
,
Sujenthiran
A
,
Cathcart
P
,
van der Meulen
J
, et al.
Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer
.
BJU Int
.
2022
;
130
(
2
):
262
–
70
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Gouveia
AG
,
Moraes
FY
,
Lima
RP
,
Viani
GA
.
Impact of COVID-19 on the curative treatment of prostate cancer: a national cross-sectional study
.
Rep Pract Oncol Radiother
.
2022
;
27
(
4
):
659
–
65
.
Google Scholar
PubMed
 
7.
Bernstein
AN
,
Talwar
R
,
Handorf
E
,
Syed
K
,
Danella
J
,
Ginzburg
S
, et al.
Assessment of prostate cancer treatment among black and white patients during the COVID-19 pandemic
.
JAMA Oncol
.
2021
;
7
(
10
):
1467
–
73
.
Google Scholar
PubMed
 
8.
Filipas
DK
,
Pose
RM
,
Marks
P
,
Tennstedt
P
,
Beyer
B
,
Tilki
D
, et al.
Impact of COVID-19 on the time to counseling and treatment of prostate cancer
.
Aging Male
.
2024
;
27
(
1
):
2347465
.
Google Scholar
PubMed
 
9.
Oppolzer
IA
,
Schnabel
MJ
,
Hammer
S
,
Zilles
H
,
Haas
M
,
Goßler
C
, et al.
Impact of SARS-CoV-2 pandemic on diagnosis of prostate cancer
.
Urol Int
.
2024
:
1
–
9
.
Google Scholar
 
10.
Gore
JL
,
Follmer
K
,
Reynolds
J
,
Nash
M
,
Anderson
CB
,
Catto
JWF
, et al.
Interruptions in bladder cancer care during the COVID-19 public health emergency
.
Urol Oncol
.
2024
;
42
(
4
):
116 e17
–
e21
.
Google Scholar
PubMed
 
11.
Wei
Y
,
Yang
X
,
Zhu
H
,
Zhuang
J
,
Cai
L
,
Ji
Q
, et al.
Impact of the COVID-19 pandemic on bladder cancer patients: a multicenter real-world study
.
J Int Med Res
.
2023
;
51
(
10
):
3000605231204465
.
Google Scholar
PubMed
 
12.
Tulchiner
G
,
Staudacher
N
,
Fritz
J
,
Hackl
M
,
Pichler
M
,
Seles
M
, et al.
Seasonal variations in the diagnosis of testicular germ cell tumors: a national cancer registry study in Austria
.
Cancers
.
2021
;
13
(
21
):
5377
.
Google Scholar
PubMed
 
13.
Yildiz
AK
,
Ozgur
BC
,
Bayraktar
AS
,
Demir
DO
,
Doluoglu
OG
.
How has the COVID-19 pandemic affected patients with primary bladder cancer
.
Cir Cir
.
2023
;
91
(
2
):
204
–
11
.
Google Scholar
PubMed
 
14.
Janes
WCI
,
Fagan
MG
,
Andrews
JM
,
Harvey
DR
,
Warden
GM
,
Johnston
PH
, et al.
Impacts of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation
.
Can Urol Assoc J
.
2024
;
18
(
4
):
E113
–
9
.
Google Scholar
PubMed
 
15.
Srivastava
A
,
Patel
HV
,
Kim
S
,
Shinder
B
,
Sterling
J
,
Tabakin
AL
, et al.
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: oncologic implications in the COVID-19 era and beyond
.
Urol Oncol
.
2021
;
39
(
5
):
247
–
57
.
Google Scholar
PubMed
 
16.
Taheri
D
,
Jahanshahi
F
,
Khajavi
A
,
Kafi
F
,
Pouramini
A
,
Farsani
RM
, et al.
The impact of covid-19 pandemic on genitourinary cancers stage and grade
.
Clin Genitourin Cancer
.
2023
;
21
(
1
):
84
–
90
.
Google Scholar
PubMed
 
17.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 2020, AWMF-Registrierungsnummer 032/038OL. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/ (accessed April 12th, 2023).
18.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL. Available from: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ (accessed date 29, 2023).
19.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 4.0, 2023, AWMF-Registernummer: 043-017OL. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/ (accessed date 24, 2023).
20.
Chang
SS
,
Bochner
BH
,
Chou
R
,
Dreicer
R
,
Kamat
AM
,
Lerner
SP
, et al.
Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
.
J Urol
.
2017
;
198
(
3
):
552
–
9
.
Google Scholar
PubMed
 
21.
Witjes
JA
,
Bruins
HM
,
Cathomas
R
,
Comperat
EM
,
Cowan
NC
,
Gakis
G
, et al.
European association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines
.
Eur Urol
.
2021
;
79
(
1
):
82
–
104
.
Google Scholar
PubMed
 
22.
Reike
MJ
,
Reicherz
A
,
Tully
KH
,
Bahlburg
H
,
Maas
M
,
Bach
P
, et al.
An empirical survey on the adaption of neoadjuvant chemotherapy in bladder cancer
.
Urol Int
.
2024
;
108
(
3
):
183
–
9
.
Google Scholar
PubMed
 
© 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.